The U.S. Food and Drug Administration (FDA) approved Oriahnn on May 29, 2020.

The U.S. FDA has granted approval to EPKINLY® (epcoritamab-bysp) for individuals with relapse or refractory (R/R) follicular lymphoma (FL).

The U.S. Food and Drug Administration (FDA) approved Tauvid on May 28, 2020.

Lyell Immunopharma Announces Phase 1 Results for ROR1-targeted CAR-T Candidate, LYL797, Showing Dose-dependent Efficacy Enhanced by Anti-exhaustion Technology.

The U.S. Food and Drug Administration (FDA) approved Phexxi on May 22, 2020.

Simcere Zaiming, announced that their new anti-EGFR antibody treatment, Enlituo®, has been officially approved for sale by the China National Medical Administration.

Cerianna (fluoroestradiol F 18) is FDA approved. The U.S. Food and Drug Administration (FDA) approved Cerianna on May 20, 2020.

6.24-6.30 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

The U.S. Food and Drug Administration (FDA) approved Ripretinib on May 15, 2020, for the treatment of advanced gastrointestinal stromal tumor (GIST) in adult patients who have received prior treatment with three or more kinase inhibitors, including imatinib.

HUADONG MEDICINE Reports Encouraging Phase I Outcomes for New Oral GLP-1 Receptor Agonist HDM1002.

The U.S. Food and Drug Administration (FDA) approved Selpercatinib on May 8, 2020, under an accelerated approval process.

Star Therapeutics Unveils Clinical Findings on VGA039, an Injectable Therapy for Von Willebrand Disease (VWD).